Genotyping of the Resistance Determinant of Neisseria Gonorrhoeae with Reduced Susceptibility to Ceftriaxone in Manaus-AM-Brazil

William Antunes Ferreira¹, Waldemara De Souza Vasconcelos², Jairo De Souza Gomes³, Maria De Fátima Pinto Da Silva³, Felipe Gomes Naveca⁴ and Cristina Motta Ferreira⁴

¹PhD in Tropical and Infectious Disease, Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta-FUAM, Brazil
²Pathology Technician, Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta-FUAM, Brazil
³PhD in Science (Microbiology), Instituto Leônidas e Maria Deane-FIOCRUZ-AM, Brazil
⁴PhD in Tropical and Infectious Disease, 3Fundação de Hematologia e Hemoterapia do Amazonas –FHEMIOAM, Brazil

Revisited: 18 May, 2017; Accepted: 15 June, 2017; Published: 28 June 2017

*Corresponding author: William Antunes Ferreira, PhD in Tropical and Infectious Disease, Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta-FUAM, Manaus-Amazonas, Brazil. Tel: 55-9236325844; E-mail: wianfe@yahoo.com.br

Abstract

Gonorrhea is the second most prevalent sexually transmitted infection worldwide, with an estimated 78.3 million new cases. At the Alfredo da Matta foundation, gonorrhea is the main cause of urethral discharge with prevalence of 16.8%. Gonococci have developed resistance to all the antibiotics leaving cephaporsins as the last option for treatment. In this current report, we genotype the determinants of resistance to Extended Spectrum Cephalosporins, such as penA, ponA, porB, mtrR, pilQ, of a Neisseria gonorrhoeae strain, isolated from a male patient with urethral discharge. The ST1901 was identified by MLST protocol and genotyping of the penA showed mutations on regions F505L, A511V, A517G, N542H and P522S which confirmed the presence of gonococcus with reduced susceptibility to ceftriaxone in the region.

Keywords: Genotyping; MLST; N. Gonorrhoeae; Cephaloporsin; Resistance

Text

In last few decades, gonococci have developed resistance to all the antibiotics used as first line of treatment for gonococcal infections, leaving Extended Spectrum Cephalosporins (ESCs) as the last remaining option for gonorrhea [1,2]. With reports of reduced susceptibility or resistance to ESCs from different regions, and due to therapeutic limitations, the infection has become a serious health problem to the point that disease complications can no longer be treated in the near future, besides the possibility of the gonococcus to evolve into “superbug” [3-7].

Gonorrhea is the second most prevalent sexually transmitted infection worldwide, with an estimated 78.3 million new cases in 2012 [8]. At the Alfredo da Matta foundation (Manaus-Brazil), gonorrhea appears as the main cause of urethral discharge, with an average of 513 cases in 20 years and prevalence of 16.8%. In this report, we describe the molecular characteristics of the N. gonorrhoeae strain NgFUAM84, isolated from the urethral discharge of a male patient, with MIC of 0.064μg/mL for ceftriaxone in E-test (AB Biodisk, Solna, Sweden) [9]. The determinants of resistance to ESCs: penA, ponA, porB, mtrR and pilQ were amplified by PCR (Proflex PCR System-Applied Biosystems) using primers previously described [10,11]. The sequencing of amplicons was performed on the ABI 3130 Genetic Analyzer (Applied Biosystems). The substitutions in the residues were analyzed using the software Geneious v.10.0.10 and identified by comparison with the sequences deposited in GenBank (Figure 1).

The molecular epidemiology was determined by Multi Locus Sequence Typing, performed according to the guidelines described in [http://pubmlst.org/neisseria]. Clinical aspects, phenotypic characteristics, antimicrobial susceptibility test, analysis of the genes gyrA and parC, and identification of the ST225 for the NG-MAST (http://www.ng-mast.net) was performed as described earlier [9]. The NgFUAM84 was not beta-lactamase producer and were resistant to Ciprofloxacin (> 32 g/mL), Chloramphenicol (3 g/mL), Ofloxacin (> 32 g/mL), reduced susceptibility to Penicillin (0.75 g/mL) and Tetracycline (0.75 g/mL) [9]. The genotyping by MLST identified ST1901; clone associated with reduced sensibility and resistance to ECSs and is predominant worldwide [1].

Analysis of the gene ponA showed a single mutation at the L421P position, whereas in the gene mtrR, a single deletion of adenine (A) in the inverted position of the promoter region was identified. The NgFUAM84 also presented resistance determinant penB with substitutions at position G120K, A121D of loop 3 of PorB181. These mutations have been associated with reduced sensitivity and resistance of gonococci to ECSs [6,14]. A single substitution on position G554D was identified in PilQ (Table 1). Analysis of the penA made possible identification of substitutions at positions F505L, A511V, A517G and P522S. The PBP2 protein showed similarity of 99.3% with the XXIV allele (GenBank...
accession number: FJ465093 and 99.7% and with strain NJ5 GenBank accession number: KF576657 [3,6]. Changes in the susceptibility of gonococcus to ceftriaxone were previously detected in Manaus however; genotyping of those strains was not performed. Recent studies (unpublished) show that gonococci circulating in the region are still sensitive to the ESCs, however, elevated MICs to ceftriaxone has been detected [15]. Other authors have associated the presence of PBP2 mosaic alleles and mutations at A501V and A501T positions with reduced sensitivity and resistance to cefixime and ceftriaxone [5,7,14]. We did not identify these substitutions in NgFUAM84, however, the MIC of 0.064μg/mL reinforces the possibility that non-mosaic penA mutations can increase the MICs of ESCs similar to those mediated by mosaic allele [3].

The mutations observed in the resistance determinants of ESCs in NgFUAM84 strain as well the identification of STs 225 and 1901, confirm the presence of gonococci with reduced susceptibility to ceftriaxone in the region and reinforces the need for monitoring of the susceptibility of gonococcus to these antibiotics and extensive research for better understanding of the resistance’s mechanisms in order to maximize the effectiveness of ESCs in the treatment of gonorrhea. [4].

**Figure 1:** Cladogram of full-length of FUAM84’s penA sequence with reference FA1090 (NC002946) and others: NgLM306 (NGOPENA-M32091.0) ; NgFA19; (NZ_AKCG00000000.1)WT ; NgYMC/Ng02/37 (FJ465093.1) Lee¹ ; Ng0202 (AB511946) Ohnishi; NgNJ-5 (KF576657.1) Li¹ ; NgH041 (AB546858) Ohnishi² ; Ng0003 (AB511945) Ohnishi³ ; (HQ204552) NgXXXIV and (HQ204565) NgXXXVIII Allen¹ ; (IF893455.1) NgXXXIX Martin unpublished. The arrow represents the rate of the sample of the study.

**Table 1:** Genotype characteristics - NgFUAM84

<table>
<thead>
<tr>
<th>Gene</th>
<th>Mutations</th>
<th>GenBank Access n°</th>
</tr>
</thead>
<tbody>
<tr>
<td>penA</td>
<td>F505L, A511V, A517G and P552S</td>
<td>MF048800</td>
</tr>
<tr>
<td>ponA</td>
<td>LA21P</td>
<td>MF062527</td>
</tr>
<tr>
<td>porB</td>
<td>G120K, A121D</td>
<td>MF048801</td>
</tr>
<tr>
<td>mtrR</td>
<td>Deleção A</td>
<td>MF095076</td>
</tr>
<tr>
<td>pilQ</td>
<td>G554D</td>
<td>MF095077</td>
</tr>
</tbody>
</table>

• Presence of the extra codon on positions 346 of NgFUAM84. PBP2
Acknowledgment

Prof. Dr. Ana Milka Dhyani, Júlio César Lima Sampaio and Victor Costa de Souza

References


